Free Trial
→ Your free book is about to disappear (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aflac Incorporated stock logo
AFL
Aflac
$127.44
+0.7%		$118.47
$105.76
▼
$131.18
$62.57B0.551.67 million shs1.75 million shs
LGN stock logo
LGN
LGN
$35.00
-3.5%		$46.11
$23.90
▼
$107.24
$3.92B3.422.18 million shs2.39 million shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$308.79
-2.4%		$301.71
$175.89
▼
$326.63
$6.33B1.16215,877 shs129,023 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aflac Incorporated stock logo
AFL
Aflac
+0.81%+2.78%+7.92%+4.99%+11.23%
LGN stock logo
LGN
LGN
-3.50%+25.40%-22.07%-47.27%+3,499,999,900.00%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-2.37%+0.85%+4.68%+4.82%+50.18%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aflac Incorporated stock logo
AFL
Aflac
$127.44
+0.7%		$118.47
$105.76
▼
$131.18
$62.57B0.551.67 million shs1.75 million shs
LGN stock logo
LGN
LGN
$35.00
-3.5%		$46.11
$23.90
▼
$107.24
$3.92B3.422.18 million shs2.39 million shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$308.79
-2.4%		$301.71
$175.89
▼
$326.63
$6.33B1.16215,877 shs129,023 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aflac Incorporated stock logo
AFL
Aflac
+0.81%+2.78%+7.92%+4.99%+11.23%
LGN stock logo
LGN
LGN
-3.50%+25.40%-22.07%-47.27%+3,499,999,900.00%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-2.37%+0.85%+4.68%+4.82%+50.18%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aflac Incorporated stock logo
AFL
Aflac
2.06
Hold$118.73-6.83% Downside
LGN stock logo
LGN
LGN
2.80
Moderate Buy$93.33166.67% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
2.89
Moderate Buy$355.3815.09% Upside

Current Analyst Ratings Breakdown

Latest AFL, LGN, and LGND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
LGN stock logo
LGN
LGN
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform
11/13/2026
LGN stock logo
LGN
LGN
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$100.00 ➝ $60.00
11/12/2026
Aflac Incorporated stock logo
AFL
Aflac
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetEqual Weight$116.00 ➝ $124.00
11/12/2026
Aflac Incorporated stock logo
AFL
Aflac
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetUnderperform$112.00 ➝ $117.00
11/11/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$345.00 ➝ $350.00
11/9/2026
Aflac Incorporated stock logo
AFL
Aflac
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$138.00 ➝ $143.00
11/5/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$397.00 ➝ $402.00
11/3/2026
Aflac Incorporated stock logo
AFL
Aflac
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeBuy (B+) ➝ Buy (A-)
11/2/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy (B) ➝ Hold (C)
10/30/2026
LGN stock logo
LGN
LGN
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
10/30/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$345.00 ➝ $357.00
(Data available from 11/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aflac Incorporated stock logo
AFL
Aflac
$17.16B3.67$9.38 per share13.58$59.21 per share2.15
LGN stock logo
LGN
LGN
$2.55B1.48$0.60 per share58.39$7.49 per share4.67
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$268.09M23.04$7.67 per share40.28$48.08 per share6.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aflac Incorporated stock logo
AFL
Aflac
$3.65B$6.8618.5816.421.7821.24%12.82%3.30%N/A
LGN stock logo
LGN
LGN
-$59.78M$0.4097.2214.71N/A1.04%14.08%3.86%N/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$124.45M$2.24137.8538.225.5220.27%5.22%2.74%N/A

Latest AFL, LGN, and LGND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
LGN stock logo
LGN
LGN
$0.50$1.15+$0.65$1.15N/A$1.31 billion
11/4/2026Q3 2026
Aflac Incorporated stock logo
AFL
Aflac
$1.80$2.43+$0.63$0.61$4.12 billion$4.30 billion
10/29/2026Q3 2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$2.33$2.67+$0.34-$1.43$77.00 million$78.75 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aflac Incorporated stock logo
AFL
Aflac
$2.441.91%+15.68%35.57%44 Years
LGN stock logo
LGN
LGN
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A

Latest AFL, LGN, and LGND Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/12/2026
Aflac Incorporated stock logo
AFL
Aflac
quarterly$0.642.03%2/17/20272/17/20273/1/2027
11/4/2026
Aflac Incorporated stock logo
AFL
Aflac
quarterly$0.611.95%11/18/202611/18/202612/1/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aflac Incorporated stock logo
AFL
Aflac
0.30
0.11
0.11
LGN stock logo
LGN
LGN
1.03
1.35
1.35
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
0.71
1.22
1.19

Institutional Ownership

CompanyInstitutional Ownership
Aflac Incorporated stock logo
AFL
Aflac
67.44%
LGN stock logo
LGN
LGN
N/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
91.28%

Insider Ownership

CompanyInsider Ownership
Aflac Incorporated stock logo
AFL
Aflac
0.80%
LGN stock logo
LGN
LGN
0.01%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
5.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aflac Incorporated stock logo
AFL
Aflac
12,716494.61 million490.65 millionOptionable
LGN stock logo
LGN
LGN
7,000108.07 million108.06 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
4720.00 million18.88 millionOptionable

Recent News About These Companies

Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $350.00
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31198466
Ligand Pharmaceuticals (NASDAQ:LGND) Director Jason Aryeh Sells 3,000 Shares of Stock
November 13 at 5:52 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-lgnd-insider-buying-and-selling-2026-11-13/
Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 3,000 Shares of Company Stock
November 12 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-ligand-pharmaceuticals-nasdaq-lgnd-director-sells-3000-shares-of-company-stock-2026-11-12/
Ligand Pharmaceuticals (NASDAQ:LGND) Given New $350.00 Price Target at Barclays
November 11 at 10:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-ligand-pharmaceuticals-nasdaq-lgnd-given-new-35000-price-target-at-barclays-2026-11-11/
62,181 Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Villere ST Denis J & Co. LLC
November 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-62181-ligand-pharmaceuticals-incorporated-lgnd-shares-sold-by-villere-st-denis-j-co-llc-2026-11-10/
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $402.00
November 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31186197
Ligand Pharmaceuticals (NASDAQ:LGND) Director Jason Aryeh Sells 282 Shares of Company Stock
November 7, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-lgnd-insider-buying-and-selling-2026-11-07/
HC Wainwright Has Negative Opinion of LGND FY2026 Earnings
November 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31182961
Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 282 Shares of Company Stock
November 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-ligand-pharmaceuticals-nasdaq-lgnd-director-sells-282-shares-of-company-stock-2026-11-06/
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Citigroup Analyst Says
November 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-ligand-pharmaceuticals-nasdaq-lgnd-stock-price-expected-to-rise-citigroup-analyst-says-2026-11-05/
HC Wainwright Has Bearish Estimate for LGND FY2026 Earnings
November 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-has-bearish-estimate-for-lgnd-fy2026-earnings-2026-11-05/
Ligand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 Shares of Stock
November 5, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-lgnd-insider-buying-and-selling-2026-11-05/
Ligand Pharmaceuticals Insider Sold Shares Worth $1,566,094, According to a Recent SEC Filing
November 4, 2026  |  marketscreener.comM
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells $1,566,100.00 in Stock
November 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-ligand-pharmaceuticals-nasdaq-lgnd-insider-sells-156610000-in-stock-2026-11-04/
Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 700 Shares of Company Stock
November 4, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-lgnd-insider-buying-and-selling-2026-11-04/
Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells $224,301.00 in Stock
November 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-ligand-pharmaceuticals-nasdaq-lgnd-director-sells-22430100-in-stock-2026-11-03/
Ligand Pharmaceuticals (NASDAQ:LGND) Director Jason Aryeh Sells 1,411 Shares of Stock
November 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-ligand-pharmaceuticals-nasdaq-lgnd-director-jason-aryeh-sells-1411-shares-of-stock-2026-11-03/
Ligand Pharmaceuticals Incorporated $LGND Stock Purchased by Profund Advisors LLC
November 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ligand-pharmaceuticals-incorporated-lgnd-stock-purchased-by-profund-advisors-llc-2026-11-02/
Ligand Pharmaceuticals (LGND) Stock Price Ignores Q3 Earnings Losses And Royalty Strength
October 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-lgnd-stock-price-170936190.html
Royal Bank Of Canada Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price
October 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-royal-bank-of-canada-issues-positive-forecast-for-ligand-pharmaceuticals-nasdaq-lgnd-stock-price-2026-10-30/
Ligand Pharmaceuticals Incorporated 2026 Q3 - Results - Earnings Call Presentation
October 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4960304-ligand-pharmaceuticals-incorporated-2026-q3-results-earnings-call-presentation

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aflac stock logo

Aflac NYSE:AFL

$127.44 +0.93 (+0.73%)
Closing price 11/13/2026 03:59 PM Eastern
Extended Trading
$127.28 -0.16 (-0.12%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan. The Aflac U.S. segment provides cancer, accident, short-term disability, critical illness, hospital indemnity, dental, vision, long-term care and disability, and term and whole life insurance products in the United States. It sells its products through sales associates, brokers, independent corporate agencies, individual agencies, and affiliated corporate agencies. Aflac Incorporated was founded in 1955 and is headquartered in Columbus, Georgia.

LGN stock logo

LGN NASDAQ:LGN

$35.00 -1.27 (-3.50%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$35.02 +0.02 (+0.06%)
As of 11/13/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Legence Corp. is a provider of engineering, consulting, installation and maintenance services for mission-critical systems in buildings. The company specializes in designing, fabricating and installing complex HVAC, process piping and other mechanical, electrical and plumbing systems. Legence Corp. is based in SAN JOSE, Calif.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$308.79 -7.48 (-2.37%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$308.07 -0.72 (-0.23%)
As of 11/13/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas